Biopharmaceutical company Assembly Biosciences, Inc. is at the forefront of developing therapeutic candidates to treat hepatitis B virus (HBV) infection in the United States. The company's cutting-edge HBV core inhibitors, such as ABI-4334 and ABI-H3733, are currently in Phase 1a and Phase 1b clinical studies respectively, and the company's research also includes small molecule approaches to HBV and hepatitis delta virus (HDV). Assembly Biosciences, Inc. has also entered into several collaboration agreements to further develop and commercialize its product candidates, including with BeiGene, Ltd. for chronic HBV infection in China, Hong Kong, Taiwan, and Macau, as well as clinical trial collaboration with Arbutus Biopharma Corporation and Antios Therapeutics, Inc. Additionally, the company's Herpesvirus programs feature the long-acting helicase inhibitor ABI-5366 HSV-2 and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in the biotech hub of South San Francisco, California.
Assembly Biosciences Inc's ticker is ASMB
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 51-200 employees working at Assembly Biosciences Inc
It is http://www.assemblybio.com/
Assembly Biosciences Inc is in the Healthcare sector
Assembly Biosciences Inc is in the Biotechnology industry
The following five companies are Assembly Biosciences Inc's industry peers: